Citations

Showing 10 of 108083 citations.

A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization
Mead, Gillian , Yperzeele, Laetitia , Wu, Simiao , Cheyne, Joshua , Wahab, Kolawole , Urrutia, Victor , Sylaja, PN , Steiner, Thorsten , Liebeskind, David S, Liebeskind, David S. , Mead, Gillian E , Yperzeele, Laetitia , Wu, Simiao , Urrutia, Victor C , Sylaja, P N , Steiner, Thorsten , Rabinstein, Alejandro A , Liebeskind, David S. , Sposato, Luciano A. , Silva, Gisele Sampaio , Kutlubaev, Mansur Amirovich , Sharma, Vijay K, Hill, Kelvin M , Rabinstein, Alejandro A.

Mayo Clinic

International Journal of Stroke | February 1, 2023 | Volume: 18 | Issue: 5 | Pages: 499-531

10.1177/17474930231156753 | PMID 36725717 Get It

Background: There are multiple stroke guidelines globally. To synthesize these and summarize what existing stroke guidelines recommend about the management of people with stroke, the World Stroke Organization (WSO) Guideline committee, under the auspices of the WSO, reviewed available guidelines. Aims: To systematically review the literature to identify stroke guidelines (excluding primary stroke prevention and subarachnoid hemorrhage) since 1 January 2011, evaluate quality (The international Appraisal of Guidelines, Research and Evaluation (AGREE II)), tabulate strong recommendations, and judge applicability according to stroke care available (minimal, essential, advanced). Summary of review: Searches identified 15,400 titles; 911 texts were retrieved, 200 publications scrutinized by the three subgroups (acute, secondary prevention, rehabilitation), and recommendations extracted from most recent version of relevant guidelines. For acute treatment, there were more guidelines about ischemic stroke than intracerebral hemorrhage; recommendations addressed pre-hospital, emergency, and acute hospital care. Strong recommendations were made for reperfusion therapies for acute ischemic stroke. For secondary prevention, strong recommendations included establishing etiological diagnosis; management of hypertension, weight, diabetes, lipids, and lifestyle modification; and for ischemic stroke, management of atrial fibrillation, valvular heart disease, left ventricular and atrial thrombi, patent foramen ovale, atherosclerotic extracranial large vessel disease, intracranial atherosclerotic disease, and antithrombotics in non-cardioembolic stroke. For rehabilitation, there were strong recommendations for organized stroke unit care, multidisciplinary rehabilitation, task-specific training, fitness training, and specific interventions for post-stroke impairments. Most recommendations were from high-income countries, and most did not consider comorbidity, resource implications, and implementation. Patient and public involvement was limited. Conclusion: The review identified a number of areas of stroke care where there was strong consensus. However, there was extensive repetition and redundancy in guideline recommendations. Future guideline groups should consider closer collaboration to improve efficiency, include more people with lived experience in the development process, consider comorbidity, and advise on implementation.
A Comparison of Outcomes following Plate versus Pin Fixation of Metacarpal Shaft and Neck Fractures
Nelson, Benjamin A. , Trentadue, Taylor P. , Somasundaram, V. , Patel, Priya , Capo, John T., Rizzo, Marco , Nelson, Benjamin Alan , Somasundaram, Vivek, Trentadue, Taylor P , Nelson, Benjamin A., Somasundaram, Vivek

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | February 1, 2023 | Volume: 11 | Issue: 1 | Pages: e4741

10.1097/gox.0000000000004741 | PMID 36699237 Get It

Background: The aim of this study is to compare clinical and radiographic outcomes of open reduction and internal fixation versus closed reduction and percutaneous pinning of metacarpal fractures in relation to anatomic and surgical variables. Methods: Electronic medical records at two institutions were reviewed for patients who underwent surgical intervention for metacarpal fractures. Data were collected from those who underwent reduction and internal fixation with either plates or Kirschner wires (K-wires). Inclusion criteria included minimum postoperative follow-up of 60 days and age 18 years or older. Exclusion criteria included insufficient radiographic data, previously attempted closed reduction with immobilization, pathologic fracture mechanism, history of previous trauma or surgery to the affected bone, and fixation technique other than plate or K-wire. Results: We reviewed data for patients treated over a 22-year time period. Ultimately, 81 metacarpal shaft and neck fractures in 60 patients met inclusion criteria. Among all metacarpal fractures, complications were present in 39 (48.1%) cases. There were no significant associations between complication prevalence and hardware type. Revision surgery was required in 11 (13.6%) patients; there were no significant associations between revision procedures and hardware type. Postoperatively, all patients with imaging data had radiograph follow-up to assess union status. There was no significant association between time to union and hardware type. Conclusions: Outcomes showed no significant difference between plate and pin fixation for metacarpal shaft and neck fractures. These findings suggest that surgeons may have flexibility to decide on the type of operative intervention while considering patient-specific factors, such as the need for early mobilization.
Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
Baksh, Sheriza , Heath, Sonya L. , Fukuta, Yuriko , Shade, David , Bloch, Evan M. , Spivak, Emily S , Patel, Bela , Gerber, Jonathan M. , Forthal, Donald N. , Blair, Janis E. , Cachay, Edward R. , Currier, Judith S. , Das, Piyali, Huamán, Moisés A. , Yarava, Anusha , Baksh, Sheriza N , Anjan, Shweta , Blair, Janis, Currier, Judith , Casadevall, Arturo , Huaman, Moises A , Meisenberg, Barry R. , Tobian, Aaron A.R. , Raval, Jay S. , Paxton, James H , Mosnaim, Giselle S , Anjan, Shweta , Sutcliffe, Catherine G , Casadevall, Arturo , Sullivan, David , Hanley, Daniel F. , Gebo, Kelly A

Mayo Clinic

The Journal of Infectious Diseases | February 1, 2023 | Volume: 227 | Issue: 11 | Pages: 1266-1273

10.1093/infdis/jiad023 | PMID 36722044 Get It

Abstract Background Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) reduces hospitalizations among outpatients treated early after symptom onset. It is unknown whether CCP reduces time to symptom resolution among outpatients. Methods We evaluated symptom resolution at day 14 by trial arm using an adjusted subdistribution hazard model, with hospitalization as a competing risk. We also assessed the prevalence of symptom clusters at day 14 between treatments. Clusters were defined based on biologic clustering, impact on ability to work, and an algorithm. Results Among 1070 outpatients followed up after transfusion, 381 of 538 (70.8%) receiving CCP and 381 of 532 (71.6%) receiving control plasma were still symptomatic (P = .78) at day 14. Associations between CCP and symptom resolution by day 14 did not differ significantly from those in controls after adjustment for baseline characteristics (adjusted subdistribution hazard ratio, 0.99; P = .62). The most common cluster consisted of cough, fatigue, shortness of breath, and headache and was found in 308 (57.2%) and 325 (61.1%) of CCP and control plasma recipients, respectively (P = .16). Conclusions In this trial of outpatients with early COVID-19, CCP was not associated with faster resolution of symptoms compared with control. Overall, there were no differences by treatment in the prevalence of each symptom or symptom clusters at day 14. Clinical Trials Registration NCT04373460.
Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer’s disease
Corriveau‐Lecavalier, Nick , Barnard, Leland R , Lee, Jeyeon , Dicks, Ellen , Botha, Hugo , Graff‐Radford, Jonathan , Boeve, Bradley F. , Lowe, Val J. , Petersen, Ronald C. , Jones, David T. , Jones, David T , Boeve, Brad , Botha, Hugo , Corriveau-Lecavalier, Nick , Machulda, Mary M. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Cerebral Cortex | February 1, 2023 | Volume: 33 | Issue: 11 | Pages: 7026-7043

10.1093/cercor/bhad017 | PMID 36721911 Get It

Abstract Dysexecutive Alzheimer’s disease (dAD) manifests as a progressive dysexecutive syndrome without prominent behavioral features, and previous studies suggest clinico-radiological heterogeneity within this syndrome. We uncovered this heterogeneity using unsupervised machine learning in 52 dAD patients with multimodal imaging and cognitive data. A spectral decomposition of covariance between FDG-PET images yielded six latent factors (“eigenbrains”) accounting for 48% of variance in patterns of hypometabolism. These eigenbrains differentially related to age at onset, clinical severity, and cognitive performance. A hierarchical clustering on the eigenvalues of these eigenbrains yielded four dAD subtypes, i.e. “left-dominant,” “right-dominant,” “bi-parietal-dominant,” and “heteromodal-diffuse.” Patterns of FDG-PET hypometabolism overlapped with those of tau-PET distribution and MRI neurodegeneration for each subtype, whereas patterns of amyloid deposition were similar across subtypes. Subtypes differed in age at onset and clinical severity where the heteromodal-diffuse exhibited a worse clinical picture, and the bi-parietal had a milder clinical presentation. We propose a conceptual framework of executive components based on the clinico-radiological associations observed in dAD. We demonstrate that patients with dAD, despite sharing core clinical features, are diagnosed with variability in their clinical and neuroimaging profiles. Our findings support the use of data-driven approaches to delineate brain–behavior relationships relevant to clinical practice and disease physiology.
Portopulmonary hypertension: May we agree to disagree?
Krowka, Michael J. , Kamath, Patrick S.

Mayo Clinic

Liver Transplantation | February 1, 2023 | Volume: 29 | Issue: 4 | Pages: 349-350

10.1097/lvt.0000000000000078 | PMID 36724441 Get It

Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group
Whiteway, Susan L. , Allen‐Rhoades, Wendy , Avutu, Viswatej , Indelicato, Daniel J. , Isakoff, Michael S. , Janeway, Katherine A. , Patel, Shreyaskumar , Riedel, Richard F. , Thornton, Katherine A., Ahmed, Safia K. , Avutu, Viswatej , Reed, Damon R , Riedel, Richard F , Allen-Rhoades, Wendy A , Indelicato, Daniel J , Weiss, Aaron R. , Cardona, Kenneth , Davis, Lara E. , Davis, Elizabeth J. , Livingston, J. Andrew , Reed, Damon R. , Kopp, Lisa M.

Mayo Clinic

Journal of Adolescent and Young Adult Oncology | February 1, 2023 | Volume: 12 | Issue: 5 | Pages: 792-793

10.1089/jayao.2022.0179 | PMID 36724495 Get It

Medication Management in the Critically Ill Patient with Acute Kidney Injury
Frazee, Erin N. , Flannery, Alexander H , Frazee, Erin N , Behal, Michael L.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | February 1, 2023 | Volume: 18 | Issue: 8 | Pages: 1080-1088

10.2215/cjn.0000000000000101 | PMID 36723347 Get It

Abstract AKI occurs frequently in critically ill patients. Patients with AKI, including those who require KRT, experience multiple pharmacokinetic and pharmacodynamic perturbations that dynamically influence medication effectiveness and safety. Patients with AKI may experience both subtherapeutic drug concentrations, which lead to ineffective therapy, and supratherapeutic drug concentrations, which increase the risk for toxicity. In critically ill patients with AKI not requiring KRT, conventional GFR estimation equations, especially those based on serum creatinine, have several limitations that can limit the accuracy when used for medication dosing. Alternative methods to estimate kidney function may be informative, including use of measured urinary creatinine clearance, kinetic eGFR, and equations that integrate novel kidney biomarkers. For critically ill patients with AKI requiring KRT, physicochemical properties of the drug, the KRT prescription and circuit configuration, and patient-specific factors each contribute to medication clearance. Evidence-based guidance for medication dosing during AKI requiring KRT is often limited. A working knowledge of the basic tenets of drug elimination during KRT can provide a framework for how to approach decision making when the literature is lacking. Iterative re-evaluation of a patient's progress toward therapeutic goals with a medication must occur over the arc of critical illness, including and especially in the setting of dynamic kidney function.
Iatrogenic Nerve Injuries of the Upper Extremity
Crowe, Christopher S. , Shin, Alexander Y. , Pulos, Nicholas , Shin, Alexander Y , Pulos, Nicholas

Mayo Clinic

JBJS Reviews | February 1, 2023 | Volume: 11 | Issue: 1 | Pages: No page available

10.2106/jbjs.rvw.22.00161 | PMID 36722824 Get It

» Iatrogenic nerve injuries may occur after any intervention of the upper extremity. » Causes of iatrogenic nerve lesions include direct sharp or thermal injury, retraction, compression from implants or compartment syndrome, injection, patient positioning, radiation, and cast/splint application, among others. » Optimal treatment of iatrogenic peripheral nerve lesions relies on early and accurate diagnosis. » Advanced imaging modalities (e.g., ultrasound and magnetic resonance imaging) and electrodiagnostic studies aid and assist in preoperative planning. » Optimal treatment of iatrogenic injuries is situation-dependent and depends on the feasibility of direct repair, grafting, and functional transfers.
Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis
Sperry, Brett W. , Hanna, Mazen , Maurer, Mathew S. , Nativi-Nicolau, José , Stewart, Michelle, Barsdorf, Alexandra I., Kapadia, Heli, Spertus, John A. , Spertus, John A , Sperry, Brett W , Maurer, Mathew S , Floden, Lysbeth , Stewart, Michelle, Wyrwich, Kathleen W.

Mayo Clinic

JAMA Cardiology | February 1, 2023 | Volume: 8 | Issue: 3 | Pages: 275

10.1001/jamacardio.2022.5251 | PMID 36723935 Get It

ImportanceTafamidis reduced all-cause mortality and cardiovascular-related hospitalizations and minimized patient-reported health status deterioration at 30 months in patients with transthyretin (ATTR) amyloidosis. However, the clinical significance of health status changes remains unclear, particularly in patients with New York Heart Association (NYHA) class III symptoms who experienced more cardiovascular-related hospitalizations than those with NYHA class I-II symptoms.ObjectiveTo evaluate the health status of patients taking tafamidis with baseline NYHA class III symptoms.Design, Setting, and ParticipantsThis randomized clinical trial post hoc analysis evaluated data for patients with transthyretin (ATTR) cardiac amyloidosis and NYHA class I-III symptoms at baseline who were enrolled in ATTR-ACT, a placebo-controlled study of tafamidis held at 48 sites in 13 countries.InterventionsTafamidis meglumine, 80 mg or 20 mg (pooled cohort), vs placebo.Main Outcomes and MeasuresEstablished thresholds for clinical benefit on the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) were used to define response groups (very large decline to very large improvement); the proportion of patients in each group was calculated within each baseline NYHA class.ResultsAmong 441 patients (264 tafamidis, 177 placebo), the mean (SD) age was 74.3 (7.0) years; 398 (90%) were male and 43 (10%) were female. Mean (SD) baseline KCCQ-OS scores were 67.3 (21.4) in the tafamidis group and 65.9 (21.7) in the placebo group (range: 0-100, with 100 indicating the best health). There was a significant shift toward better KCCQ-OS scores in patients receiving tafamidis (odds ratio for 10-point improvement 2.4; 95% CI, 1.6-3.4; P < .001). More patients taking tafamidis were alive and not worse at all time points (37% vs 15% at month 30). These findings were similar in patients with NYHA class III symptoms. In patients with NYHA class III symptoms alive at 30 months, improvements in health status were more common (35% vs 10%) and declines were less common (38% vs 57%) with tafamidis vs placebo.Conclusions and RelevanceIn ATTR-ACT, although patients with baseline NYHA class III symptoms had worse overall outcomes, treatment with tafamidis yielded better health status compared with placebo.Trial RegistrationClinicalTrials.gov Identifier: NCT01994889